- Reaction score
- 214
The phase II clinical trial was a multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of KX-826 for the treatment of male Androgenetic Alopecia adults (N=120). The primary endpoint for the trial was the change from baseline in non-vellus target area hair counts (TAHC) at week 24 in comparison with placebo.
The majority of adverse events (AEs) were mild and no serious adverse event (SAE) was reported. KX-826 was well-tolerated and no new safety signals were observed. Detailed data will be released later upon the finalization of the clinical study report. 5mg (0.5%) KX-826 was determined as the dose to be taken into phase III clinical trial in China, which we expect to kick off the work in Q4 2021.
en.kintor.com.cn
The majority of adverse events (AEs) were mild and no serious adverse event (SAE) was reported. KX-826 was well-tolerated and no new safety signals were observed. Detailed data will be released later upon the finalization of the clinical study report. 5mg (0.5%) KX-826 was determined as the dose to be taken into phase III clinical trial in China, which we expect to kick off the work in Q4 2021.
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met_Kintor Pharmaceutical Limited
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met-Kintor Pharmaceutical Limited-Suzhou, September 8, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology company developing...